Watson Will Focus On Breeding Narrow; Leaf Indica And High Terpene Cannabis Varieties
DENVER, CO / ACCESSWIRE / August 24, 2017 / United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today announced the appointment of David Watson to the Company's Advisory Board.
Mr. Watson, founder and Chief Executive Officer of HortaPharm B.V., the world's first established medical cannabis corporation, is renowned in the industry. Credited by many for assembling the world's most comprehensive cannabis-seed library, he is also responsible for securing protection for 29 cultivars under the International Union for the Protection of New Varieties of Plants (UPOV) breeder's rights.
Selfing, the proprietary breeding technique developed under his guidance, resulted in HortaPharm becoming the world's first breeder to develop homozygote cannabis, in which both sets of chromosomes are identical. This facilitates the mass production of plants with a consistent cannabinoid profile; a critical factor in pharmaceutical development. To that end, in 1998, HortaPharm began working with GW Pharmaceuticals, assisting it in selecting and supplying the cultivars used to produce Sativex®, and other GW products.
Mr. Watson is also co-founder of the International Hemp Association, a non-profit educational group dedicated to the advancement of cannabis through the dissemination of information, and an activist working in the United States and internationally to change laws regarding the cultivation of industrial hemp. Mr. Watson co-authored Hemp Diseases and Pests (2000) and contributed to Cannabis and Cannabinoids, Marijuana and Cannabinoids. He has also written a number of peer-reviewed articles.
The Company's Advisory Board is tasked with helping the Company advance and protect the development of its proprietary formulations, including managing the clinical trial process, patent protection, new product research, and development, as well as identifying and pursuing potential strategic relationships and markets. Mr. Watson's focus will be the development of NLD equatorial and tropical recreational varieties and industrial varieties as well as high terpene varieties.
Commenting on the appointment, Mr. Watson stated, "I look forward to working with United Cannabis to develop cannabis varieties with unique cannabinoid and terpene profiles."
Earnest Blackmon, Chief Executive Officer of United Cannabis, added, "We are thrilled to announce that David has joined our Advisory Board. He is legendary within the industry, and his knowledge regarding the identification and cultivation of specific cannabis varieties will be indispensable as we continue our efforts to create effective cannabis-centric compounds to assist patients suffering from a broad spectrum of conditions. I cannot wait to begin working closely with him."
About United Cannabis Corporation
The Company's Prana Bio Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purpose. These products, licensed to regulated marijuana dispensaries, are broken into 5 categories that are available in capsules, sublingual's, and topical delivery methods. The Company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability.
For further information, please visit www.unitedcannabis.us.
Contact: [email protected]
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors, created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE: United Cannabis Corporation